FRMM
Forum MarketsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The balance sheet improved meaningfully by quarter-end, and the RWA tokenization / ETH-yield strategy could create option value if management turns the pivot into repeatable assets and cash flow.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Management explicitly warns that failure to commercialize RWA plans could leave the company vulnerable to shell-company style risk again.
Momentum
37
Value
42
Sentiment
18
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.40 · Bull $5.20 · Bear $1.90
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum37 · Δ7d -36.1
Value42 · Δ7d +0.1
Sentiment18 · Δ7d +2.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
37
34% active weight
Current posture
7d trendSoftening
Δ7d
-36.1
Δ21d
-59.5
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
18
33% active weight
Current posture
7d trendImproving
Δ7d
+2.2
Δ21d
-
Why this grade
Composite grade F. Momentum 36.9 / Value 41.9 / Sentiment 17.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$66.46M
Beta
1.19
Shares Out
19.01M
P/E (TTM) · Derived
-0.0
P/S (TTM)
24.79
P/FCF (TTM) · Derived
-0.61
Rev YoY
-
EPS YoY
-209.5%
Gross Margin
-
Op Margin
-5445.2%
Net Debt
-$4.43M
Current Ratio
10.07
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology